|
Market Closed -
Nasdaq
16:00:00 2026-11-06 EST
|
5-day change | 1st Jan Change | ||
| 26.84 USD | +4.07% |
|
-0.07% | -23.71% |
| 10-28 | Viking Therapeutics, Inc., Q3 2026 Earnings Call, Oct 28, 2026 | |
| 10-28 | Earnings Flash (VKTX) Viking Therapeutics Posts Q3 Loss -$1.55, vs. FactSet Est of -$1.06 Loss | MT |
Company Valuation: Viking Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 359.9 | 720.9 | 1,862 | 4,484 | 3,977 | 3,289 | - | - |
| Change | - | 100.31% | 158.23% | 140.89% | -11.32% | -17.3% | - | - |
| Enterprise Value (EV) 1 | 157.8 | 565.4 | 1,499 | 3,582 | 3,271 | 2,887 | 2,856 | 3,196 |
| Change | - | 258.34% | 165.21% | 138.86% | -8.68% | -11.75% | -1.05% | 11.88% |
| P/E | -6.48x | -10.4x | -20.5x | -39.8x | -11x | -4.94x | -5.24x | -7x |
| PBR | 1.78x | 4.97x | 5.35x | 5.1x | 6.32x | 7.69x | 8.29x | -153x |
| PEG | - | -0.4x | -18.45x | -3.6x | -0x | -0.1x | 0.92x | 0.3x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 17.3x |
| EV / Revenue | - | - | - | - | - | - | - | 16.8x |
| EV / EBITDA | -2.83x | - | -14.9x | -23.7x | -8.32x | -4.45x | -4.18x | -6.74x |
| EV / EBIT | -2.83x | -8.04x | -14.9x | -23.7x | -8.32x | -4.38x | -4.22x | -5.77x |
| EV / FCF | -3.32x | -11.7x | -20.4x | -40.8x | -4.69x | -4.98x | -4.74x | -5.48x |
| FCF Yield | -30.2% | -8.56% | -4.89% | -2.45% | -21.3% | -20.1% | -21.1% | -18.2% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.71 | -0.9 | -0.91 | -1.01 | -3.19 | -5.431 | -5.123 | -3.832 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 190 |
| EBITDA 1 | -55.68 | - | -100.8 | -150.9 | -393.3 | -648.1 | -683.7 | -474.1 |
| EBIT 1 | -55.68 | -70.36 | -100.8 | -150.9 | -393.3 | -658.5 | -676.4 | -554.2 |
| Net income 1 | -54.99 | -68.87 | -85.9 | -110 | -359.6 | -648.3 | -655.3 | -507.1 |
| Net Debt 1 | -202.1 | -155.5 | -362.1 | -902.6 | -705.7 | -402.3 | -432.5 | -93.26 |
| Reference price 2 | 4.60 | 9.40 | 18.61 | 40.24 | 35.18 | 26.84 | 26.84 | 26.84 |
| Nbr of stocks (in thousands) | 78,235 | 76,688 | 100,029 | 111,436 | 113,036 | 127,522 | - | - |
| Announcement Date | 2/9/22 | 2/8/23 | 2/7/24 | 2/5/25 | 2/11/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.75x | - | -4.45x | - | 3.29B | |
| 18.32x | 6.97x | 13.35x | 1.63% | 69.4B | |
| 30.72x | 8.25x | 27.72x | 0.05% | 57.24B | |
| 39.18x | 6.93x | 20.69x | 0.83% | 57.62B | |
| 34.57x | 3.29x | 14.19x | -.--% | 43.65B | |
| 51.08x | 5.91x | 32.37x | -.--% | 44.03B | |
| -18.44x | 177.78x | -19.56x | -.--% | 38.08B | |
| 36.57x | 9x | 23.45x | 0.36% | 36.31B | |
| 44.16x | 7.87x | 26.34x | -.--% | 32.61B | |
| 29.41x | 6.22x | 16.14x | -.--% | 25.47B | |
| Average | 26.08x | 25.80x | 15.02x | 0.32% | 40.77B | |
| Weighted average by Cap. | 29.05x | 22.92x | 17.44x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- VKTX Stock
- Valuation Viking Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
